Brief: Natco Pharma Concludes US FDA Inspection At Chennai API Unit
21/11/2025 14:29
Nov 21 (Reuters) - Natco Pharma Ltd NATP.NS: NATCO PHARMA - CONCLUDES US FDA INSPECTION AT CHENNAI API UNIT NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS IN FORM-483 POST INSPECTION Source text: ID:nBSE9x88yr Further company coverage: NATP.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees